Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2001

View Archived Issues

A novel tumor suppressor gene activated by Ras available for licensing from NIH

Preliminary U.S. testing of Alprox-TD in severe ED patients completed

Avax makes notable progress in AC vaccine development program during 2000

Phase III trial of IntraBiotics' oral ramoplanin experiences delay

Boston Life Sciences reports successful phase II outcome with Altropane for ADHD diagnosis

Millennium and Abbott form alliance in metabolic disease

Chiron BLA for HIV-1 and HCV diagnostic accepted by FDA

Human factor Xa inhibitor JTV-803 is a promising orally active antithrombotic agent

Novel nonpeptide compound Y-40018 displays high selectivity for human chymase

Potential new treatment for dermatitis evaluated in animal models of contact hypersensitivity

Aromatase inhibitor effective in infertile women with unsatisfactory response to clomiphene

TranXenoGen licenses novel anticancer protein

High-dose, long-term atorvastatin therapy may reduce atherosclerosis progression

Patient enrollment complete in AstraZeneca's CHARM program for heart failure

Second-generation Vitaxin enters phase I evaluation for treatment of solid tumors

Clinical trial results support once-daily desloratadine as safe, effective antiallergic medication

MedImmune's UTI vaccine enters second phase II trial

Hollis-Eden files IND for clinical evaluation of HE-2200

ETA antagonist TBC-3214 emerges from structure-bioavailability studies as clinical candidate

Neuroprotective series claimed by Vernalis

Ceramide analogues from Bracco induce apoptosis in cancer cells

Almirall Prodesfarma presents new phosphodiesterase inhibitors

Schering prepares vitamin D derivatives with improved side effect and metabolic profile

Antiprotozoal apicidin derivatives that act by inhibiting histone deacetylase

High-affinity, selective 5-ht6 receptor ligands emerge from research at Merck

Japanese patent issued to Kissei for inhibitors of cathepsin and papain

Metabotropic glutamate receptor antagonists and their use

Antiviral agents discovered at Bayer particularly useful against cytomegalovirus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...